publication venue for
- Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an international observational study. 2022
- Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH). 2022
- Stenting of ductus venosus as a palliation for portal hypertension because of neonatal cirrhosis.. 42. 2022
- Liver involvement in children with SARS-COV-2 infection: Two distinct clinical phenotypes caused by the same virus.. 41. 2021
- Factors associated with health-related quality of life in patients with cirrhosis: a systematic review.. 41. 2020
- MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.. 40. 2020
- Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.. 40. 2020
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.. 39. 2019
- The rise of Clostridioides difficile infections and fall of associated mortality in hospitalized advanced cirrhotics.. 39. 2019
- HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: Results from ERCHIVES.. 38. 2018
- Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.. 38. 2017
- Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list.. 38. 2017
- Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.. 36. 2016
- Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.. 36. 2015
- High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy.. 35. 2014
- Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.. 34. 2013
- Activation of FoxO3a/Bim axis in patients with Primary Biliary Cirrhosis.. 33. 2013
- Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study.. 32. 2012
- Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality.. 32. 2011
- Hepatitis C treatment completion rates in routine clinical care.. 30. 2009
- Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients.. 29. 2009
- Pretransplant variables associated with quality of life in liver transplant recipients.. 28. 2008
- Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis.. 25. 2005
- MARS preconditioning for living donor liver transplantation: panacea or placebo?. 25. 2005
- Optimal treatment with telaprevir for chronic HCV infection. 2013
- Endocannabinoids and liver disease--review. 2005
- The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis. 2023
- Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: Evidence and perspectives. 2020